Neuroinflammatory component of gray matter pathology in multiple sclerosis
- 30 September 2016
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 80 (5) , 776-790
Abstract
Objective: In multiple sclerosis (MS), using simultaneous magnetic resonance–positron emission tomography (MR‐PET) imaging with 11C‐PBR28, we quantified expression of the 18kDa translocator protein (TSPO), a marker of activated microglia/macrophages, in cortex, cortical lesions, deep gray matter (GM), white matter (WM) lesions, and normal‐appearing WM (NAWM) to investigate the in vivo pathological and clinical relevance of neuroinflammation.Methods: Fifteen secondary‐progressive MS (SPMS) patients, 12 relapsing–remitting MS (RRMS) patients, and 14 matched healthy controls underwent 11C‐PBR28 MR‐PET. MS subjects underwent 7T ‐weighted imaging for cortical lesion segmentation, and neurological and cognitive evaluation. 11C‐PBR28 binding was measured using normalized 60‐ to 90‐minute standardized uptake values and volume of distribution ratios.Results: Relative to controls, MS subjects exhibited abnormally high 11C‐PBR28 binding across the brain, the greatest increases being in cortex and cortical lesions, thalamus, hippocampus, and NAWM. MS WM lesions showed relatively modest TSPO increases. With the exception of cortical lesions, where TSPO expression was similar, 11C‐PBR28 uptake across the brain was greater in SPMS than in RRMS. In MS, increased 11C‐PBR28 binding in cortex, deep GM, and NAWM correlated with neurological disability and impaired cognitive performance; cortical thinning correlated with increased thalamic TSPO levels.Interpretation: In MS, neuroinflammation is present in the cortex, cortical lesions, deep GM, and NAWM, is closely linked to poor clinical outcome, and is at least partly linked to neurodegeneration. Distinct inflammatory‐mediated factors may underlie accumulation of cortical and WM lesions. Quantification of TSPO levels in MS could prove to be a sensitive tool for evaluating in vivo the inflammatory component of GM pathology, particularly in cortical lesions. Ann Neurol 2016;80:776–790Keywords
Funding Information
- Clafin Award
- National Multiple Sclerosis Society (NMSS) (RG 4729A2/1)
- US Army, Department of Defense (W81XWH-13-1-0112)
- NMSS fellowship (FG-1507-05459)
- ARSEP Foundation
- Italian Multiple Sclerosis Foundation (2012/B/04)
- NIH (1R21NS087472-01A1)
- DOD (W81XWH-14-1-0543)
This publication has 49 references indexed in Scilit:
- Increased PK11195 PET binding in the cortex of patients with MS correlates with disabilityNeurology, 2012
- Advances in understanding gray matter pathology in multiple sclerosis: Are we ready to redefine disease pathogenesis?BMC Neurology, 2012
- Inflammatory Cortical Demyelination in Early Multiple SclerosisNew England Journal of Medicine, 2011
- An 18-kDa Translocator Protein (TSPO) Polymorphism Explains Differences in Binding Affinity of the PET Radioligand PBR28Journal of Cerebral Blood Flow & Metabolism, 2011
- Demyelination causes synaptic alterations in hippocampi from multiple sclerosis patientsAnnals of Neurology, 2010
- Translocator Protein PET Imaging for Glial Activation in Multiple SclerosisJournal of Neuroimmune Pharmacology, 2010
- Comparison of [11C]-(R)-PK 11195 and [11C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: Implications for positron emission tomographic imaging of this inflammation biomarkerNeuroImage, 2010
- Brain morphometry with multiecho MPRAGENeuroImage, 2008
- Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammationNeuroImage, 2008
- Rating neurologic impairment in multiple sclerosisNeurology, 1983